PCSK9 inhibitor therapy and guideline treatment targets for cardiovascular disease and familial hypercholesterolaemia

27 August 2021 (08:00 - 20:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Mr Anirudh Suresh

Chelsea and Westminster Hospital NHS Trust, London (United Kingdom of Great Britain & Northern Ireland)

57 More presentations in this session

Presentation thumbnail

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Doctor J. Borovac (Split, HR)

Abstract Slides

Presentation thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Doctor A. KANWAL (Valhalla, US)

Abstract Slides

Presentation thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Doctor K. Dzaurova (Moscow, RU)

Abstract Slides

Presentation thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Mrs A. Boulmpou (Nijmegen, NL)

Abstract Slides

Presentation thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Mrs A. Boulmpou (Nijmegen, NL)

Abstract Slides

Access the full session

Session thumbnail

Pharmacology and pharmacotherapy e-posters

The Event

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Webinar

New trial evidence in the field of lipid management

Congress Presentation

2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias